Importantly, we further confirmed that targeting the Th17 niche or deleting CXCL16 inhibits Ph+ B-ALL progression and exhibits a synergistic therapeutic effect in combination with imatinib in vivo. This evidence concerns the gene CXCL16 and acute lymphoblastic leukemia.